Sector News

Reports: Allergan In Advanced Talks To Acquire Salix Pharmaceuticals

September 24, 2014
Life sciences
(RTTNews.com) – Botox maker Allergan Inc. is in advanced talks to buy Salix Pharmaceuticals Ltd. in order to fend off a $53 billion hostile bid from Canada-based Valeant Pharmaceuticals Inc., according to media reports on Monday. Shares of Salix gained more than 10 percent in extended trades following the media reports.
 
A deal could reportedly be announced later this week or in the next week. However, Raleigh, North Carolina-based Salix Pharma is itself merging with a unit of Italy’sCosmo Pharmaceuticals SpA as part of a tax-inversion deal. Tax inversion is the process of moving a company’s headquarters overseas to benefit from cheaper tax rates compared to higher tax rates in the U.S.
 
Irvine, California-based Allergan’s acquisition of Salix would likely halt a hostile bid for the company from Valeant Pharma and also mean the end of Salix’s deal to acquire Cosmo Technologies. Salix has a market capitalization of $10.18 billion.
 
In April, Valeant along with billionaire investor William Ackman’s hedge fund Pershing Square made a hostile bid to acquire Allergan for $46 billion in cash and stock. Pershing Square is the largest shareholder in Allergan with a 9.7 percent stake. However, Allergan’s board rejected the offer.
 
In May, Valeant sweetened its bid for Allergan to about $53 billion, but the offer was again spurned. Allergan has called Valeant’s business model unsustainable and said that a deal with Valeant would hurt its research and development program.
 
Allergan has agreed to unconditionally call and hold a special meeting of its shareholders on December 18. At the special meeting, Pershing Square plans to rejig the Allergan board and push forward the takeover bid.
 
Meanwhile, pharmaceutical company Actavis plc also reportedly made an offer to acquire Allergan. Terms of the deal were not known, but Allergan is said to have rejected the offer as it was focused on finalizing a deal with Salix.
 
Allergan could pay for the acquisition of Salix with cash and thus, sidestep the need for a shareholder vote on the deal with Valeant Pharmaceuticals and Pershing Square.
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”